UPDATE: Morgan Stanley Upgrades Novartis (NOVN:SW) (NVS) to Overweight

September 1, 2020 4:26 AM EDT
Get Alerts NOVN:SW Hot Sheet
Price: $0.00 --0%

Rating Summary:
    0 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 18 | Down: 13 | New: 23
Trade Now! 
Join SI Premium – FREE
(Updated - September 1, 2020 7:15 AM EDT)

(updating comment)

Morgan Stanley analyst Mark Purcell upgraded Novartis (NOVN:SW) (NYSE: NVS) from Equalweight to Overweight with a price target of CHF101.00 (from CHF93.00).

The analyst comments "Greater focus on execution risks and rising concerns that future growth could grind to a halt without M&A support has seen Novartis shares de-rate by 20% vs peers. We argue 2021
will be an execution reward year, with the emergence of hidden pipeline assets not reflected in the current valuation."


You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change, Hot Comments, Hot Upgrades, Intl Ratings, Upgrades

Related Entities

Morgan Stanley